Findings

What do systematic reviews say?

4,752 questions · 6,648 findings · 688 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,125 · 16.9%GRADE not reported 670 · 10.1%Very low 1,796 · 27%Low 1,685 · 25.3%Moderate 1,075 · 16.2%High 297 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings: BT vs external beam radiotherapy (EBRT)

Mean GI symptom scores · People with urological (prostate) and gynaecological (endometrial) cancer

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 348 participants
GRADE not reported

Mineral trioxide aggregate (MTA) vs 3Mix (ciprofloxacin + metronidazole + minocycline)

Radiological failure · Children with extensive decay involving the dental pulp in primary teeth

1 finding from 1 review

Pulp treatment for extensive decay in primary teeth 2018 · Cochrane All outcomes
12 months
No radiological failure in any participant (Aminabadi 2016); not estimable
1 study · 160 participants
GRADE not reported

Buprenorphine vs methadone

Mean days in treatment · Adults with opioid dependence

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 82 participants
Low

Buprenorphine vs methadone

Number completing withdrawal treatment · Adults with opioid dependence

Buprenorphine showed no clear difference in completion of withdrawal treatment compared with methadone (moderate certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
RR 1.04 [0.91, 1.2]
5 studies · 457 participants
Moderate

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Clearing or excellent improvement · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
GRADE not reported

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

At least 50% reduction in erythema · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Quality of life measure · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonates vs placebo/observation

Median time to a skeletal‐related event · women with advanced breast cancer without bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Low

Bisphosphonates vs placebo/observation

Overall survival · women with advanced breast cancer without bone metastases

Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 0.89 [0.73, 1.09]
3 studies · 330 participants
High

Bisphosphonates vs placebo/observation

Quality of life · women with advanced breast cancer without bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 124 participants
Moderate

Bisphosphonates vs placebo/observation

Skeletal‐related event (SRE) · women with metastatic breast cancer with bone metastases

Bisphosphonates leads to lower skeletal‐related event (SRE) compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 0.86 [0.78, 0.95]
9 studies · 2810 participants
High

Bisphosphonates vs placebo/observation

Median time to a skeletal‐related event · women with metastatic breast cancer with bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 2891 participants
High

Bisphosphonates vs placebo/observation

Overall survival · women with metastatic breast cancer with bone metastases

Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (moderate certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 1.01 [0.91, 1.11]
7 studies · 1935 participants
Moderate

Bisphosphonates vs placebo/observation

Bone pain · women with metastatic breast cancer with bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 3297 participants
Moderate

Bisphosphonates vs placebo/observation

Quality of life · women with metastatic breast cancer with bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1888 participants
Moderate

Hearing loss prevention programme vs audiometric testing (hearing loss)

Hearing loss STS ≥ 10 dB hearing loss average over 2, 3, 4 kHz in either ear · agricultural students without hearing loss

Hearing loss prevention programme showed no clear difference in hearing loss STS ≥ 10 dB loss average over 2, 3, 4 kHz in either ear compared with audiometric testing (hearing loss) (moderate certainty).

2 findings from 1 review

Interventions to prevent occupational noise‐induced hearing loss 2017 · Cochrane Headline outcomes only
OR 0.85 [0.29, 2.44]
1 study · 687 participants
Moderate
Interventions to prevent occupational noise‐induced hearing loss 2017 · Cochrane Headline outcomes only
OR 0.94 [0.46, 1.91]
1 study · 355 participants
Moderate

Oral vs intravenous fluoropyrimidines

Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy

Oral may leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (low certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
OR 0.17 [0.15, 0.18]
29 studies · 11794 participants
Low

Oral vs intravenous fluoropyrimidines

Progression‐free survival · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy

Oral probably leads to higher progression‐free survival compared with intravenous fluoropyrimidines (moderate certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.06 [1.02, 1.11]
23 studies · 9927 participants
Moderate